medigraphic.com
Academia Mexicana de Neurología, A.C.

2006, Number 1

<< Back Next >>

Rev Mex Neuroci 2006; 7 (1)

Neurotropic viruses: JC virus and the progressive multifocal leukoencephalopathy

Cedeno F, Penalva de OAC, Vidal JE, Trujillo JR

Language: Spanish
References: 63
Page: 46-54
PDF size: 167.75 Kb.


ABSTRACT

Neurovirology is that branch of the medical sciences that studies viruses which affect the nervous system. JC virus is a typical DNA neurotropic virus that causes a demyelinating disorder, termed Progressive Multifocal Leukoencephalopathy (PML). Approximately 80% of general population shows antibodies directed against JC virus; however, seroconversion is mainly asymptomatic. PML cases have been lately recognized with a higher frequency that parallels the increased number of AIDS cases and also the immunosuppression era due to transplants and antitumoral therapy. The rapid evolution of cognitive, motor and visual impairment and the sudden death in absence of treatment turns PML into an attractive disease to study and in a timely and hardly explored area for the development of new and more effective forms of therapy. In this review, we describe the molecular biology of JC virus, its neuropathogenesis, clinical manifestations and the newest diagnosis and therapy advances. In addition, we describe prospects in genetic therapy and vaccines.


REFERENCES

  1. Amstrom KE, Mancall EL, Richardson EP Jr. Progresssive multifocal leukoencephalopathy. Brain 1958; 81: 93-127.

  2. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186: 180-6.

  3. Cavanaugh JB, Greenbaum D, Marshall A, et al. Cerebral demyelination associated with disorders of reticuloendothelial system. Lancet 1959; 2: 524-29.

  4. Padget BL, ZuRhein GM, Walker DL, Eckroade RJ. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1: 1257-60.

  5. Flaegstad T, Ronne K, Filipe AR, et al. Prevalence of anti BK virus antibody in Portugal and Norway. Scand J Infect Dis 1989; 21: 145-7.

  6. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973; 127: 467-70.

  7. Shah KV, Daniel RW, Warszawski RM. High prevalence of antibodies to BK virus, an SV 40-related papovavirus, in residents of Maryland. J Infect Dis 1973; 128: 784-7.

  8. Gardner SD. Prevalence in England of antibody to human polyomavirus (B.K.). Br Med J 1973; 1: 77-8.

  9. Dei R, Marmo F, Corte D, et al. Age-related changes in the prevalence of precipitating antibodies to BK virus in infants and children. J Med Microbiol 1982; 15: 285-91.

  10. Holman RC, Janssen RS, Buehler JW, et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: Analysis of national mortality and AIDS surveillance data. Neurol 1991; 41: 1733-6.

  11. Johnson RT, Major EO. Infectious demyelinating diseases. In: Myelin biology and disorders. Vol 2. Elsevier Academic Press; 2004; 953-83.

  12. Fink MCDS, Penalva de Oliveira AC, Milagres FAP, Vidal JE, Picerno-Pouza AF, Duarte Neto A, Pannuti CS. JC virus DNA in cerebrospinal fluid simples from Brazilian AIDS patients with focal brain lesions without mass effects. Journal of Infection 2005; 16: 1-7.

  13. Frisque RJ, Bream GL, et al. Human polyomavirus JC virus genome. J NeuroVirol 1984; 7: 548-469.

  14. Okada Y, Endo S, et al. Distribution and function of JCV agnoprotein. J Virol 2001; 104: 130-6.

  15. Staib C, Pesch J, et al. p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T antigen. Virol 1996; 219: 87-100.

  16. Power C, Gladden JG, et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurol 2000; 54: 743-6.

  17. Richardson-Burns SM, et al. Progressive multifocal leukoencephalopathy and apoptosis of infected oligoden-drocytes in the central nervous system of patients with and without AIDS. Arch Neurol 2002; 59: 1930-6.

  18. London WT, Houff SA, et al. Brain tumors in owl monkeys inoculated with a human polyomavirus (JC virus) 1978; 201: 1246-9.

  19. Chang D, Fung CY, et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells, J Gen Virol 1997; 78: 1435-9.

  20. Goldman C, Petry H, Frye S, Ast O. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999; 73: 4465–9.

  21. Frisque RJ. Structure and function of JC virus T’ proteins. J Neuro Virol 2001; 7: 293-7.

  22. Darbinyan A, Darbinyian N, et al. Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene 2002; 21: 5574-81.

  23. Major EO. Human polyomavirus in: Fields: Virology. Lippincott Williams and Wilkins (eds.) 2001; 2175-96.

  24. Liu CK, Wei G, et al. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha (2-6) linked sialic acids. J Virol 1998; 72: 4643-9.

  25. Pho MT, Ashok A, et al. JC virus enters human glial cells by clathrin-dependent receptor mediated endocytosis. J Virol 2000; 74: 2288-92.

  26. Raj GV, Khalili K. Transcription regulation: lessons from the human neurotropic polyomavirus, JCV. Virol 1995; 213: 283-91.

  27. Sumner C, Shinohara T, et al. Multiple class expression of the nuclear factor-1 family in the developing human brain: brain differential expression of two classes of the NF-1 genes. J Neurol Virol 1996; 2: 87-100.

  28. Trujillo R. El nacimiento de la Neurovirología en las Américas. Rev Mex Neurocienc 2000; 1: 4-7.

  29. Zurhein GM. Particles resembling papovavirus in human cerebral demyelination disease. Scienc 1965; 148: 163-9.

  30. Wroblewska Z, Wellish M, Bilden D. Growth of JC virus in adult human brain cell cultures. Arch Virol 1980; 65: 141-8.

  31. Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes and tonsillar stromal cells; implications for viral latency. J Virol 1996; 70: 704-12.

  32. Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the non-coding regulatory region. J Neurol Virol 2001; 7: 280-7.

  33. Agostini HT, Jobes DV, Stoner GL. Molecular evolution and epidemiology of JC virus. In: Human polyomaviruses: molecular perspectives. John Wiley and Sons (eds.) 2001; 491-526.

  34. Demeter L. JC, BK and other polyomaviruses; progressive multifocal leukoencephalopathy. In: Mandell: Principles and practice of infectious diseases. Churchill Livingstone 2000; 1645-54.

  35. Koralnik IJ, Wuthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, Morgello S. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57: 576-80.

  36. Du Pasquier RA, Corey S, Margolin DH, Williams K, Pfister LA, De Girolami U, Mac Key JJ, Wuthrich C, , Koralnik IJ. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurol 2003; 23(61): 775-82.

  37. Mossakowski MJ, Zelman IB. Pathomorphological variations of the AIDS-associated progressive multifocal leukoencephalopathy. Folia Neuropathol 2000; 38: 91-100.

  38. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. J Neurosurg 1985; 62: 475-95.

  39. Berger JR, Scott G, Albrecht J, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS. 1992; 6: 837-41.

  40. Vandersteenhoven JJ, Dbaibo G, Boyko OB, et al. Progressive multifocal leukoencephalopathy in pediatric acquired immunodeficiency syndrome. J Pediatr Infect Dis 1992; 11: 232-7.

  41. De Luca A, Giancola ML, et al. Potent antirretroviral therapy with or without cidofovir for AIDS associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J Neurol Virol 2001; 7: 364-8.

  42. Yiannoutsos CT, Major EO, Curfman B, Jensen PN, Hou J, Clifford DB. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999; 8: 16-21.

  43. McCance DJ, Mims CA. Reactivation of polyoma virus in kidneys of persistently infected mice during pregnancy. Infect Immun 1979; 25: 998-1002.

  44. Trujillo JR, García-Ramos G, Novak IS, Rivera VM, Huerta E, Essex M. Neurologic manifestations of AIDS: a comparative study of two populations from Mexico and the United States. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1995; 8: 23-9.

  45. Gildenberg PL, Langford L, Kim JH, Trujillo JR. Stereotactic biopsy in cerebral lesions of AIDS. Acta Neurochir 1993; 58: 68-70.

  46. Shah KV, Daniel RW, Strickler HD, Goedert JJ. Investigation of human urine for genomic sequences of the primate polyomaviruses simian virus 40, BK virus and JC virus. J Infect Dis 1997; 176: 1618-21.

  47. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy: A hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin’s disease. Brain 1958; 81: 93-110.

  48. Richardson EP Jr. Progressive multifocal leukoencephalopathy. N Engl J Med 1961; 265: 815-23.

  49. Richardson EP Jr, Webster HDF. Progressive multifocal leukoencephalopathy: its pathological features. Prog Clin Biol Res 1983; 105: 191-203.

  50. Berger JR, Kaszovitz B, Post MJ, et al. Progressive multifocal and in diseased tissues. J Infect Dis 1983; 147(4): 676-84.

  51. Roberts MT. AIDS-associated progressive multifocal leukoencephalopathy: current management strategies. CNS Drugs. 2005; 19: 671-82.

  52. Wyen C, Hoffmann C, Schmeisser N, Wohrmann A, Qurishi N, Rockstroh J, Esser S, Rieke A, Ross B, Lorenzen T, Schmitz K, Stenzel W, Salzberger B, Fatkenheuer G. Progressive multifocal leukoencephalopathy in patients on highly active antirretroviral therapy: survival and risk factors of death. J Acquir Immun Defic Syndr 2004; 1(37): 1263-8.

  53. De Luca A, Ammassari A, Cingolani A, Giancola ML, Antinori A. Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antirretroviral therapy. AIDS 1998; 12: 1937-8.

  54. Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Donovan Post MJ, Ruiz A, Bowen BC, Huang ML, Queen-Baker J, Andersen J, Kelly S, Shriver S. Adult AIDS Clinical Trials Group 363 Team. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16(13): 1791-7.

  55. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Scienc 2004; 306(5700): 1380-3.

  56. Altschuler EL. The atypical antipsychotic agents ziprasidone, risperidone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencepha-lopathy. Med Hypotheses 2005; 65: 585-6.

  57. Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Mertenskotter T, Eggers C, Stellbrink HJ. Highly active antirretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998; 12: 1149-54.

  58. Przepiorka D, Jaeckle KA, Birdwell RR, Fuller GN, Kumar AJ, Huh YO, McCutcheon I. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant. 1997; 20: 983-7.

  59. Jarrett W, Smith K, O’Neil B, Gaukroger J, Chandrachud L, Grindlay G, McGarvie G, Campo M. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virol 1991; 184: 33-42.

  60. Kirnbauer R. Papillomavirus-like particles for serology and vaccine development. Intervirol 1996; 39: 54-61.

  61. McCance D. Persistence of animal and human papovavirus in renal and nervous tissues. Prog Clin Biol Res 1983; 105: 343-57.

  62. Atwood W, Ameyami K, Traub R, Harms J, Major E. Interaction of the human polyomavirus JCV with human B-lymphocytes. Virol 1992; 190: 716-23.

  63. Rieckmann P, Michel U, Kehrl J H. Regulation of JC virus expression in B lymphocytes. J Virol 1994; 68: 217-22.




2020     |     www.medigraphic.com